Antiplatelet drugs and platelet reactivity: is it time to halt clinical research on tailored strategies?

Bibliography

• Fontana P, Reny JL. New antiplatelet strategies in atherothrombosis and their indications. Eur J Vasc Endovasc Surg 2007;34(1):10-17
   PubMed Web of Science ®Google Scholar
• Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980;17(3-4):317-27
   PubMed Web of Science ®Google Scholar
• Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008;29(1):21-30
   PubMed Web of Science ®Google Scholar
• Zufferey A, Reny JL, Combescure C, et al. Platelet reactivity is a stable and global phenomenon in aspirin-treated cardiovascular patients. Thromb Haemost 2011;106(3):466-74
   PubMed Web of Science ®Google Scholar
• Reny JL, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008;6(3):444-50
   PubMed Web of Science ®Google Scholar
• Combescure C, Fontana P, Mallouk N, et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2010;8(5):923-33
   PubMed Web of Science ®Google Scholar
• Wurtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des 2012;18(33):5344-61
   PubMed Web of Science ®Google Scholar
• Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108(7):2244-7
   PubMed Web of Science ®Google Scholar
• Fontana P, Hulot JS, De Moerloose P, Gaussem P. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 2007;5(10):2153-5
   PubMed Web of Science ®Google Scholar
• Wurtz M, Lordkipanidze M, Grove EL. Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists. J Thromb Haemost 2013;11(9):1627-39
   PubMed Web of Science ®Google Scholar
• Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103(1):5-10
   PubMed Web of Science ®Google Scholar
• Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51(14):1404-11
   PubMed Web of Science ®Google Scholar
• Reny JL, Berdague P, Poncet A, et al. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the antiplatelet drug resistances and ischemic events study. Circulation 2012;125(25):3201-10
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Erlinge D, Ohman EM, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 2012;308(17):1785-94
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305(11):1097-105
   PubMed Web of Science ®Google Scholar
• Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367(22):2100-9
   PubMed Web of Science ®Google Scholar
• Bauer T, Bouman HJ, van Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011;343:d4588
   PubMed Web of Science ®Google Scholar
• Fontana P, Cattaneo M, Combescure C, Reny JL. Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping. J Am Heart Assoc 2013;2(2):e000131
   PubMed Web of Science ®Google Scholar
• Freedman JE, Iafrati HF. Use of genetics and transcriptomics in the diagnosis and treatment of coronary artery disease. Rev Esp Cardiol 2010;63(10):1123-6
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302(8):849-57
   PubMed Web of Science ®Google Scholar
• Tantry US, Gesheff M, Liu F, et al. Resistance to antiplatelet drugs: what progress has been made? Expert Opin Pharmacother 2014;15(17):2553-64
   PubMed Web of Science ®Google Scholar
• Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62(24):2261-73
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Stavrou K, Koniari I, et al. Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events. Thromb Haemost 2014;112(3):551-7
   PubMed Web of Science ®Google Scholar
• Reny J-L, Fontana P, Hochholzer W, et al. Abstract 19827: Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of major adverse cardiovascular events in patients on clopidogrel: systematic review and collaborative meta-analysis of individual patient data. Circulation 2014;130(Suppl 2):A19827
   Google Scholar
• Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomized antarctic study. Am Heart J 2014;168(5):674-81
   PubMed Web of Science ®Google Scholar
• Zufferey A, Ibberson M, Reny J-L, et al. Unraveling modulators of platelet reactivity in cardiovascular patients using omics strategies: towards a network biology paradigm. Trans Proteomic 2013;1(1):25-37
   Google Scholar